| [1] |
Rawla P, Sunkara T, Barsouk A. 2019. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Gastroenterology Review/Przegląd Gastroenterologiczny 14(2):89−103 doi: 10.5114/pg.2018.81072 |
| [2] |
Ferlay J, EM, Lam F, Laversanne M, Colombet M, Mery L, et al. 2023. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/media/globocan/factsheets/populations/360-indonesia-fact-sheet.pdf |
| [3] |
Hernandez Dominguez O, Yilmaz S, Steele SR. 2023. Stage IV colorectal cancer management and treatment. Journal of Clinical Medicine 12(5):2072 doi: 10.3390/jcm12052072 |
| [4] |
Li CJ, Zhang X, Fan GW. 2014. Updates in colorectal cancer stem cell research. Journal of Cancer Research and Therapeutics 10:C233−C239 doi: 10.4103/0973-1482.151449 |
| [5] |
O'Sullivan B, Brierley J. 2015. UICC Manual of clinical Oncology. 9th Edition. Chichester, West Sussex, UK, Hoboken, NJ: John Wiley and Sons, Ltd. doi: 10.1002/9781119013143 |
| [6] |
Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, et al. 2017. AJCC cancer staging manual. 8th Edition. Chicago, IL: American Joint Committee on Cancer, Springer. doi: 10.1007/978-3-319-40618-3 |
| [7] |
Maguire A, Sheahan K. 2014. Controversies in the pathological assessment of colorectal cancer. World Journal of Gastroenterology 20(29):9850−61 doi: 10.3748/wjg.v20.i29.9850 |
| [8] |
Pease NA, Wise-Draper T, Privette Vinnedge L. 2015. Dissecting the potential interplay of DEK functions in inflammation and cancer. Journal of oncology 2015(1):106517 doi: 10.1155/2015/106517 |
| [9] |
Lin L, Piao J, Gao W, Piao Y, Jin G, et al. 2013. DEK over expression as an independent biomarker for poor prognosis in colorectal cancer. BMC Cancer 13:336 doi: 10.1186/1471-2407-13-366 |
| [10] |
Nakashima T, Tomita H, Hirata A, Ishida K, Hisamatsu K, Hatano Y, et al. 2017. Promotion of cell proliferation by the proto-oncogene DEK enhances oral squamous cell carcinogenesis through field cancerization. Cancer Medicine 6(10):2424−39 doi: 10.1002/cam4.1157 |
| [11] |
Matrka MC, Watanabe M, Muraleedharan R, Lambert PF, Lane AN, et al. 2017. Overexpression of the human DEK oncogene reprograms cellular metabolism and promotes glycolysis. PloS One 12(5):e0177952 doi: 10.1371/journal.pone.0177952 |
| [12] |
Privette Vinnedge LM, Benight NM, Wagh PK, Pease NA, Nashu MA, et al. 2015. The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers. Oncogene 34(18):2325−36 doi: 10.1038/onc.2014.173 |
| [13] |
Lin L, Piao J, Ma Y, Jin T, Quan C, et al. 2014. Mechanisms underlying cancer growth and apoptosis by DEK overexpression in colorectal cancer. PloS one 9(10):e111260 doi: 10.1371/journal.pone.0111260 |
| [14] |
Habiburrahman M, Wardoyo MP, Sutopo S, Rahadiani N. 2022. Potential of DEK proto-oncogene as a prognostic biomarker for colorectal cancer: An evidence-based review. Molecular and Clinical Oncology 17(1):117 doi: 10.3892/mco.2022.2550 |
| [15] |
Correia C, Lee SH, Meng XW, Vincelette ND, Knorr KLB, et al. 2015. Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1853(7):1658−71 doi: 10.1016/j.bbamcr.2015.03.012 |
| [16] |
Scherr AL, Gdynia G, Salou M, Radhakrishnan P, Duglova K, et al. 2016. Bcl-xL is an oncogenic driver in colorectal cancer. Cell death & disease 7(8):e2342 doi: 10.1038/cddis.2016.233 |
| [17] |
Kunac N, Filipović N, Kostić S, Vukojević K. 2022. The expression pattern of Bcl-2 and Bax in the tumor and stromal cells in colorectal carcinoma. Medicina 58(8):1135 doi: 10.3390/medicina58081135 |
| [18] |
Ramesh P, Medema JP. 2020. BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy. Apoptosis 25(5):305−20 doi: 10.1007/s10495-020-01601-9 |
| [19] |
Freeman HJ. 2013. Early stage colon cancer. World Journal of Gastroenterology 19(46):8468−73 doi: 10.3748/wjg.v19.i46.8468 |
| [20] |
Wang J, Li S, Liu Y, Zhang C, Li H, et al. 2020. Metastatic patterns and survival outcomes in patients with stage IV colon cancer: a population-based analysis. Cancer medicine 9(1):361−73 doi: 10.1002/cam4.2673 |
| [21] |
Zhou QC, Deng XF, Yang J, Jiang H, Qiao MX, et al. 2018. Oncogene DEK is highly expressed in lung cancerous tissues and positively regulates cell proliferation as well as invasion. Oncology Letters 15(6):8573−81 doi: 10.3892/ol.2018.8436 |
| [22] |
Yang MQ, Bai LL, Wang Z, Lei L, Zheng YW, et al. 2021. DEK is highly expressed in breast cancer and is associated with malignant phenotype and progression. Oncology Letters 21(6):440 doi: 10.3892/ol.2021.12701 |
| [23] |
Yu L, Huang X, Zhang W, Zhao H, Wu G, et al. 2016. Critical role of DEK and its regulation in tumorigenesis and metastasis of hepatocellular carcinoma. Oncotarget. 7(18):26844−55 doi: 10.18632/oncotarget.8565 |
| [24] |
Riveiro-Falkenbach E, Ruano Y, García-Martín RM, Lora D, Cifdaloz M, et al. 2017. DEK oncogene is overexpressed during melanoma progression. Pigment cell & melanoma research 30(2):194−202 doi: 10.1111/pcmr.12563 |
| [25] |
Kappes F, Khodadoust MS, Yu L, Kim DSL, Fullen DR, et al. 2011. DEK expression in melanocytic lesions. Human Pathology 42(7):932−38 doi: 10.1016/j.humpath.2010.10.022 |
| [26] |
Adams AK, Hallenbeck GE, Casper KA, Patil YJ, Wilson KM, et al. 2015. DEK promotes HPV-positive and-negative head and neck cancer cell proliferation. Oncogene 34(7):868−77 doi: 10.1038/onc.2014.15 |
| [27] |
Hacker KE, Bolland DE, Tan L, Saha AK, Niknafs YS, et al. 2018. The DEK oncoprotein functions in ovarian cancer growth and survival. Neoplasia 20(12):1209−18 doi: 10.1016/j.neo.2018.10.005 |
| [28] |
Kim KM, Ahn AR, Park HS, Jang KY, Moon WS, et al. 2022. Clinical significance of p53 protein expression and TP53 variation status in colorectal cancer. BMC Cancer 22(1):940 doi: 10.1186/s12885-022-10039-y |
| [29] |
Melling N, Norrenbrock S, Kluth M, Simon R, Hube-Magg C, et al. 2019. p53 overexpression is a prognosticator of poor outcome in esophageal cancer. Oncology Letters 17(4):3826−34 doi: 10.3892/ol.2019.10020 |
| [30] |
Huang K, Chen L, Zhang J, Wu Z, Lan L, et al. 2014. Elevated p53 expression levels correlate with tumor progression and poor prognosis in patients exhibiting esophageal squamous cell carcinoma. Oncology Letters 8(4):1441−46 doi: 10.3892/ol.2014.2343 |
| [31] |
Kohler MF, Carney P, Dodge R, Soper JT, Clarke-Pearson DL, et al. 1996. p53 overexpression in advanced-stage endometrial adenocarcinoma. American Journal of Obstetrics and Gynecology 175(5):1246−52 doi: 10.1016/S0002-9378(96)70036-4 |
| [32] |
Marei HE, Althani A, Afifi N, Hasan A, Caceci T, et al. 2021. p53 signaling in cancer progression and therapy. Cancer Cell International 21(1):703 doi: 10.1186/s12935-021-02396-8 |
| [33] |
Cai X, Qi WX, Wang L, Zhang Z. 2016. Correlation of multiple proteins with clinicopathological features and its prognostic significance in colorectal cancer with signet-ring cell component. European Review for Medical & Pharmacological Sciences 20(16):3358−67 |
| [34] |
Liukkonen TJ, Lipponen PK, Helle M, Jauhiainen KE, Finnbladder III Groups. 1997. Immunoreactivity of bcl-2, p53 and EGFr is associated with tumor stage, grade and cell proliferation in superficial bladder cancer. Urological Research 25(1):1−8 doi: 10.1007/BF00941899 |
| [35] |
Yi H, Duan H, Shi W, Liu Z, Liu Y. 2021. DEK overexpression is predictive of poor prognosis in esophageal squamous cell carcinoma. Archives of Medical Science: AMS 17(1):135 doi: 10.5114/aoms.2019.84210 |
| [36] |
Zhao T, Qiu B, Zhou S, Ding G, Cao L, et al. 2019. Expression of DEK in pancreatic cancer and its correlation with clinicopathological features and prognosis. Journal of Cancer 10(4):911 doi: 10.7150/jca.27405 |
| [37] |
Lin D, Dong X, Wang K, Wyatt AW, Crea F, et al. 2014. Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer. Oncotarget 6(3):1806 doi: 10.18632/oncotarget.2809 |
| [38] |
Yang Y, Gao M, Lin Z, Chen L, Jin Y, et al. 2017. DEK promoted EMT and angiogenesis through regulating PI3K/AKT/mTOR pathway in triple-negative breast cancer. Oncotarget 8(58):98708−22 doi: 10.18632/oncotarget.21864 |
| [39] |
Ishida K, Nakashima T, Shibata T, Hara A, Tomita H. 2020. Role of the DEK oncogene in the development of squamous cell carcinoma. International Journal of Clinical Oncology 25(9):1563−69 doi: 10.1007/s10147-020-01735-5 |
| [40] |
Privette Vinnedge LM, Kappes F, Nassar N, Wells SI. 2013. Stacking the DEK: from chromatin topology to cancer stem cells. Cell Cycle 12:51−66 doi: 10.4161/cc.23121 |
| [41] |
Shibata T, Kokubu A, Miyamoto M, Hosoda F, Gotoh M, et al. 2010. DEK oncoprotein regulates transcriptional modifiers and sustains tumor initiation activity in high-grade neuroendocrine carcinoma of the lung. Oncogene 29(33):4671−81 doi: 10.1038/onc.2010.217 |
| [42] |
Garcia-Carbonero N, Martinez-Useros J, Li W, Orta A, Perez N, et al. 2020. KRAS and BRAF mutations as prognostic and predictive biomarkers for standard chemotherapy response in metastatic colorectal cancer: a single institutional study. Cells 9:291 doi: 10.3390/cells9010219 |
| [43] |
Yaeger R, Saltz L. 2012. BRAF mutations in colorectal cancer: clinical relevance and role in targeted therapy. Journal of the National Comprehensive Cancer Network 10(11):1456−58 doi: 10.6004/jnccn.2012.0148 |
| [44] |
Riveiro-Falkenbach E, Soengas MS. 2010. Control of tumorigenesis and chemoresistance by the DEK oncogene. Clinical Cancer Research 16(11):2932−38 doi: 10.1158/1078-0432.CCR-09-2330 |